Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

J Clin Oncol · 2024 · PMC10950161 · PMID 38194616

Europe PMC DOI

hedged sentence

0.2840

closest p · 5.7× alpha

0.2840

boldest claim

The sentences

did not reach statistical significanceP = .284not close (p > 0.1)

While fewer deaths were noted in the abemaciclib plus ET arm compared with the ET-alone arm, the difference in OS did not reach statistical significance (HR, 0.903 [95% CI, 0.749 to 1.088]; P = .284; Fig 1 C).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.